Guangzhou Gloria Biosciences Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2016-03-23
- Employees
- 147K
- Market Cap
- -
- Website
- https://www.gloriabio.com
Clinical Trials
8
Active:0
Completed:1
Trial Phases
3 Phases
Phase 1:3
Phase 2:2
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (37.5%)Phase 3
3 (37.5%)Phase 2
2 (25.0%)Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Phase 3
Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Motixafortide+G-CSFDrug: Placebo+G-CSF
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06514508
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Harbin The First Hospital, Harbin, Hei Longjiang, China
Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer
Phase 1
Not yet recruiting
- Conditions
- Advanced Non-Small Cell Lung Cancer
- Interventions
- Drug: GLS-012+GLS-010Drug: GLS-012+GLS-010+pemetrexed+carboplatinDrug: GLS-012+GLS-010+paclitaxel+carboplatin
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 152
- Registration Number
- NCT05978401
- Locations
- 🇨🇳
Shang Hai Pulmonary Hospital, Shanghai, Shanghai, China
Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT05909436
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Phase 3
Not yet recruiting
- Conditions
- Persistent, Recurrent, or Metastatic Cervical Cancer
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 424
- Registration Number
- NCT05798819
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China
GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)
Phase 3
Not yet recruiting
- Conditions
- Refractory Classic Hodgkin LymphomaRecurrent Classic Hodgkin LymphomaClassic Hodgkin's Lymphoma
- Interventions
- Drug: Chemotherapy of Investigator's choice
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05518318
- Prev
- 1
- 2
- Next
News
No news found